Cell therapies:why scale matters by Rafiq, Qasim A. & Hewitt, Christopher J.
97Pharm. Bioprocess. (2015) 3(2), 97–99 ISSN 2048-9145
Cell therapies: why scale matters
Qasim A Rafiq
Aston Medical Research Institute, 
School of Life & Health Sciences, 
Aston University, Aston Triangle, 
Birmingham, B4 7ET, UK 
and 
Centre for Biological Engineering, 
Loughborough University, 
Leicestershire, LE11 3TU, UK
Christopher J Hewitt
Author for correspondence: 
Aston Medical Research Institute, 
School of Life & Health Sciences, 
Aston University, Aston Triangle, 
Birmingham, B4 7ET, UK 
and 
Centre for Biological Engineering, 
Loughborough University, 
Leicestershire, LE11 3TU, UK 
Tel.: +44 (0)121 204 4949 
c.j.hewitt@aston.ac.uk
Pharmaceutical
Editorial
part of
10.4155/PBP.14.63 © 2015 Future Science Ltd
Pharm. Bioprocess.
Editorial
3
2
2015
Cell therapies provide a novel treatment 
option with the ability to replace, repair or 
regenerate damaged cells and tissue and have 
the potential to change the way in which 
medicine is practiced [1]. Unlike traditional 
biopharmaceutical manufacture where the 
cell is used as a factory for the production of 
proteins or attenuated viruses, cell therapy 
products comprise of live fully functional 
cells, which form the basis of the treatment. 
As such, the development of efficacious cell 
therapies presents new challenges whereby 
biomanufacturing processes need to account 
for cell quality from the point of isolation 
through expansion, recovery, formulation 
and final delivery to the patient. This does 
not rely solely on furthering our biological 
understanding of the cell, but also incorpo-
rates significant engineering and biomanu-
facturing hurdles, which must be simulta-
neously overcome. At present, there are over 
200 clinical trials involving human mesen-
chymal stem cells (hMSCs) alone, the major-
ity of which are in early stages of clinical tri-
als (Phase I and Phase II), and it is recognized 
that in order to meet the clinical demand for 
cells of sufficient quality and quantity, small-
scale processes for many cell therapy candi-
dates require a step change in the design of 
their corresponding manufacturing systems.
While the scientific potential of cell thera-
pies and tissue-engineered regenerative medi-
cine products has been demonstrated (e.g., tis-
sue-engineered trachea [2]), the industry has 
been hampered by limited commercial success 
and modest clinical uptake resulting primar-
ily from difficulties in establishing clinical 
utility and cost– effectiveness [3]. While the 
former is currently being addressed by com-
panies targeting ‘first-in-man’ studies, the 
latter can only be achieved by improving our 
process and product understanding such that 
cell therapy products can be manufactured at 
a suitable scale and at a price that the relevant 
reimbursement agencies are willing to bare.
It would therefore seem obvious to many 
why cell therapy processes need to be scaled, 
yet seemingly less obvious are the engineering 
and the related biological difficulties associ-
ated with large-scale production. As with early 
biopharmaceutical production, the modus 
operandi for many cell therapy candidates 
currently in development is that scalability is 
usually an afterthought and normally the final 
step in any R&D program. There is a ten-
dency to assume that given a process operates 
efficiently at the laboratory scale, it is a rela-
tively trivial matter to achieve the same level of 
efficiency and productivity at the industrial or 
production scale. However this is not the case 
with many process engineering considerations 
needing to be taken into account, it is not 
simple matter of ‘making the pot bigger’ and 
there is often a detrimental effect on biopro-
cess performance as we move up through the 
scales [4,5]. Many cell therapies currently under 
development are based on manual T-flask-
based processes, which will have to be dras-
tically redesigned to achieve the required cell 
number to meet predicted clinical demand. 
Even with autologous cell therapies where a 
scale-out approach is likely to be employed, 
the challenge of manipulating and processing 
multiple units in a closed, sterile manner can 
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“As cell therapies edge closer to commercial scale, there is a pressing 
need to understand the implications of scale up and what effect it 
will have on the cell therapy manufacturing process.”
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“Efforts are now being made in the 
biopharmaceutical industry to use relevant 
experimental scale-down models, which 
are representative of larger-scale industrial 
systems...”
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be extremely difficult. Routine processing steps such as 
passaging cells, performing medium exchanges and the 
sampling of cell culture broth require significant person-
nel and resources, or investment in automated manufac-
turing technologies which in turn involves significant 
capital expenditure and will require comparability stud-
ies between both the manual and automated processes 
before being accepted by the regulator.
For allogeneic cell therapy processes scale-up 
approaches are more likely to be employed, however, the 
challenges are even more significant from a cell expan-
sion perspective. The use of stirred-tank bioreactors for 
the scale up of biopharmaceuticals is mostly routine, 
however given that most cell therapy candidates employ 
anchorage-dependent cells, microcarriers are required 
for stirred-tank bioreactor expansion. Moving from a 
manual, T-flask-based process to a microcarrier stirred-
tank bioreactor process is a substantial transition, which 
requires significant process and product understanding. 
Furthermore, harvesting the cells from the microcarri-
ers while maintaining the cells’ critical to quality attri-
butes is very different from monolayer culture and poses 
a significant challenge, but work has begun to develop a 
scalable recovery step [6]. Indeed, we recently published 
the first peer-reviewed study of hMSC expansion and 
recovery from microcarriers in a stirred-tank bioreac-
tor at the 5-l scale (2.5-l working volume) [7], however 
for industrial scale processes, it is likely that the scale 
will need to be between 500 and 2500 l to achieve the 
predicted cell numbers required [8,9]. In essence, the 
objective of scaling up any bioprocess is to overcome the 
design conditions and operational procedures, such that 
during translation to the larger scale, the optimal envi-
ronmental conditions for the bioprocess (as identified 
at the small scale) are maintained. These environmen-
tal conditions include appropriate nutrient and growth 
inhibiting metabolite concentrations as well as main-
taining in vivo pH, temperature, dissolved oxygen and 
carbon dioxide concentrations.
Much can be learned from traditional bioprocessing 
scale up. It has often been found that for both micro-
bial and mammalian aerobic cultures, biomass yield 
and the production of growth-associated pharmaceuti-
cal products tend to decrease on scale up [4,10–12]. Such 
poor performance at the large scale is known to be due 
to the presence of spatial and temporal concentration 
gradients arising from longer mixing times and poorer 
mixing generally in comparison to the small scale when 
a fed-batch strategy (preferred by industry) is employed 
with pH control by automatic titration [4,5,13,14]. For cell 
therapies, where cell quality is of paramount impor-
tance, any fluctuations in the culture environment are 
likely to impact the product’s critical to quality attri-
butes. As such, there needs to be a greater level of atten-
tion paid to the issues that will arise during scale up, 
with a focus on the engineering characterization and 
process comparability. In particular, where large-scale 
bioreactors are being used (>0.5 m3), significant effort 
must be made to understand and characterize the mix-
ing environment within the vessel and identify any 
potential issues early on in development. It is highly 
probable that temporal and spatial gradients will indeed 
exist since a perfusion strategy is the likely way forward. 
Therefore the effects of cells circulating through such 
gradients on their quantity, quality and viability will 
need to be quantified and mechanisms of mitigating 
against these effects, if any, identified. Furthermore, to 
aid the transition through scale up, the development of 
relevant experimental scale-down models should be a 
priority, as this will ensure significant expenditure and 
resource is not wasted only to find that the process per-
forms poorly at the large scale. A novel experimental 
model for mimicking the poorly mixed conditions at 
the large scale has been devised [4] by using a small-
scale stirred-tank bioreactor connected in series with a 
plug-flow bioreactor (used to mimic the addition zone 
for nutrient feeds and pH controlling agents at the large 
scale). This model was found to be more representative 
of large-scale bioreactor performance with respect to the 
required bioprocessing outcomes than the small-scale 
stirred-tank bioreactor in isolation.
Efforts are now being made in the biopharmaceutical 
industry to use relevant experimental scale-down mod-
els, which are representative of larger-scale industrial sys-
tems [10,15] and which have proven to be successful with 
respect to screening protein-expressing clones as well 
as for the optimization of culture conditions and feed-
ing regimes for optimal cell yield and product titer [16]. 
Until now, small-scale models have primarily taken 
place in 50-ml nonsparged shake flasks [4], however 
large-scale industrial processes usually take place in the 
controlled environment of a stirred-tank bioreactor. As 
a result, bioperformance between the small-scale shake 
flask and the large-scale stirred-tank bioreactor often 
differs, with high producing clones taken forward based 
on small-scale studies which do not perform as expected 
at the large scale [16]. It has been demonstrated [10] that 
the ambr™ (TAP Biosystems, now a Sartorius Stedim 
company), a high-throughput microbioreactor system 
(15-ml maximum working volume), performed simi-
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larly with respect to cell growth and IgG4 productivity 
to that achieved in a 5-l stirred-tank bioreactor, while 
the 250-ml shake flasks run in parallel were significantly 
different [16]. It was therefore suggested that the ambr 
was a better scale-down model for clonal selection than 
the traditional shake flask model. Similar findings have 
been reported by others including biopharmaceutical 
companies such as Genentech (CA, USA) [17], Merck 
(NJ, USA) [18] and MedImmune (MD, USA) [19]. It is 
therefore our contention that suitable small-scale mod-
els which mimic cell viability, and more importantly, 
cell quality at the large scale need to be developed for 
cell therapies which may identify significant cost sav-
ings during scale up [20]. To this end, we are currently 
investigating the amenability of the ambr microbioreac-
tor system for hMSC microcarrier culture as a suitable 
high-throughput, scale-down model in place of 100-ml 
spinner flasks and initial results appear positive.
As cell therapies edge closer to commercial scale, 
there is a pressing need to understand the implica-
tions of scale up and what effect it will have on the 
cell therapy manufacturing process. These products 
rely on stringent processing conditions throughout, as 
the cells expanded at this scale are the very same cells 
that will be administered to patients. No longer should 
scale up be left to the end, but rather scalability should 
be considered early on in the development process and 
strategies should be in place from the outset to allow 
for a smooth transition from small-scale production to 
larger, clinical-scale manufacturing. If not, we may end 
up repeating the mistakes of the past and redesigning 
processes all over again.
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